Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Capital Expenditures (2017 - 2019)

GT Biopharma (GTBP) has disclosed Capital Expenditures for 3 consecutive years, with -$4000.0 as the latest value for Q4 2019.

  • On a quarterly basis, Capital Expenditures changed N/A to -$4000.0 in Q4 2019 year-over-year; TTM through Dec 2019 was -$2000.0, a N/A change, with the full-year FY2018 number at $36000.0, up 800.0% from a year prior.
  • Capital Expenditures was -$4000.0 for Q4 2019 at GT Biopharma, down from -$2000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $4000.0 in Q4 2017 to a low of -$4000.0 in Q4 2019.
  • A 3-year average of $800.0 and a median of $2000.0 in 2018 define the central range for Capital Expenditures.